Medtronic on Thursday announced that it has received FDA approval for its Percept RC and is now available in India. According to the company’s statement, this is the smallest and thinnest dual channel neurostimulator available for Deep Brain Stimulation (DBS) system, marking the latest advancement in the Percept family.
“This new rechargeable neurostimulator compliments Medtronic’s existing portfolio of devices. The Percept neurostimulators are the only DBS systems available with integrated sensing capabilities, allowing physicians to deliver highly personalized treatments for patients with movement disorders such as Parkinson’s disease, essential tremor, dystonia, and epilepsy,” the company said in a statement.
Equipped with BrainSense technology, the Percept RC captures and records brain signals, offering valuable insights that allow healthcare providers to adapt and personalize therapy to meet each patient’s changing needs, it stated.
Its rechargeable battery, powered by Medtronic’s patented technology, provides an impressive 15-year plus service life with minimal fade, ensuring consistent and reliable performance over time. Unlike other devices, the Percept RC recharges rapidly, achieving a 10 percent to 90 percent charge in under an hour, delivering convenience and dependability for patients.
“We are elated to bring the latest innovation in DBS technology to patients and clinicians in India. This cutting-edge solution aligns with the increasing demand for advanced healthcare innovations and promises a transformative impact on the treatment of complex neurological disorders. With its ability to deliver highly personalized, data-driven therapy, our new rechargeable Percept RC neurostimulator with BrainSense technology has the potential to significantly improve patient outcomes and offer a new hope for those managing the challenges of chronic neurological conditions. We look forward to empowering healthcare providers in India to set a new standard in precision care and enhanced quality of life,” Prateek Tiwari, Sr. Director, Neuroscience and Specialty Therapies, Medtronic India said.
Deep brain stimulation (DBS) uses a surgically implanted device, similar to a cardiac pacemaker. Medtronic Percept neurostimulators send electrical signals through thin wires to specific brain regions affected by neurological conditions like Parkinson’s disease, the company claims.
Nearly 70 percent of all DBS-eligible patients are estimated to require an MRI as part of their essential care. Medtronic offers full-body MR Conditional DBS systems for patients to have safe scans anywhere on the body under specific conditions, it added.
“Percept offers greater freedom and scan access for patients with 3T scans and best-in-class 1.5T MRI scan labeling. Medtronic has the only DBS system that allows patients to have stimulation on in bipolar mode during an MRI. In addition, the Percept neurostimulators are engineered to allow for future software updates designed for the Percept platform without a neurostimulator device exchange,” it stated.
